← GLP-1 receptor agonists × blood pressure

SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2025

Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.

Yihan Li et al.PubMed ↗Publisher ↗

  • Semaglutidelooks good hereLower systolic blood pressure, lower diastolic blood pressure, no clear link with diastolic blood pressure.Randomised, large.
  • Semaglutide (2.4 mg)looks good hereLower systolic blood pressure, lower diastolic blood pressure.Randomised, large.

What the trial testedrandomised · 15,347 people · 2025

Randomised vs control group

Lowered systolic blood pressure

−2.90−3.70 to −2.11

semaglutide vs control group

As reported

difference −2.90, 95% CI −3.70 to −2.11

Randomised vs control group

Lowered diastolic blood pressure

−0.86−1.34 to −0.38

semaglutide vs control group

As reported

difference −0.86, 95% CI −1.34 to −0.38

Randomised vs control group

Lowered systolic blood pressure

−4.31−5.18 to −3.44

semaglutide (2.4 mg) vs control group

As reported

difference −4.31, 95% CI −5.18 to −3.44

Randomised vs control group

Lowered diastolic blood pressure

−1.84−2.70 to −0.98

semaglutide (2.4 mg) vs control group

As reported

difference −1.84, 95% CI −2.70 to −0.98

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Semaglutide went with lower systolic blood pressure

−1.87−2.67 to −1.06

semaglutide vs control group, in non-diabetic populations

As reported

difference −1.87, 95% CI −2.67 to −1.06

Correlation · may be no link

No clear link with diastolic blood pressure

−0.43−0.89 to +0.02

semaglutide vs control group, in non-diabetic populations

As reported

difference −0.43, 95% CI −0.89 to 0.02

+1 more in the walkthrough ↓

Who was studied, and how

15,347people with hypertension, in this paper

The trial randomly assignedassigned by chance

semaglutide
control group

Lowered systolic blood pressure−2.90

Lowered diastolic blood pressure−0.86

randomised

The trial randomly assignedassigned by chance

semaglutide (2.4 mg)
control group

Lowered systolic blood pressure−4.31

Lowered diastolic blood pressure−1.84

randomised

the abstract, start to end

… pressure (SBP) (mean difference [MD] - 2.90, 95% confidence interval [CI] - 3.70 to - 2.11; P < 0.01) and diastolic blood pressure (DBP) (MD - 0.86, 95% CI - 1.34 to - 0.38; …

… a more significant reduction in SBP (- 1.87, 95% CI - 2.67 to - 1.06, vs - 5.02, 95% CI - 6.10 to - 3.94) and DBP (- 0.43, 95% CI - 0.89 to 0.02, vs …

… found to significantly lower SBP (MD - 4.31, 95% CI - 5.18 to - 3.44) and DBP (MD - 1.84, 95% CI - 2.70 to - 0.98), …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Systolic blood pressure (SBP)semaglutide vs control group
−2.90−3.70 to −2.11
Blood pressure
2.11
Diastolic blood pressure (DBP)semaglutide vs control group
−0.86−1.34 to −0.38
Systolic blood pressure (SBP)semaglutide vs control group, in non-diabetic populations
−1.87−2.67 to −1.06
Diastolic blood pressure (DBP)semaglutide vs control group, in non-diabetic populations
−0.43−0.89 to 0.02
Systolic blood pressure (SBP)semaglutide (2.4 mg) vs control group
−4.31−5.18 to −3.44
Diastolic blood pressure (DBP)semaglutide (2.4 mg) vs control group
−1.84−2.70 to −0.98
GLP-1 receptor agonistsBlood pressure

GLP-1 receptor agonists × blood pressurehelps?mixed

unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 7

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 40493329